MPM BioImpact LLC
CIK 1687078 · last filed 2025-04-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ITOS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HOWL | 10%+ Owner | 6,718,670 | $0.98 | $6.59M | -$32.2K | 1 | 2025-04-30 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 4,943,551 | $10.15 | $50.18M | -$24.60M | 7 | 2021-12-02 |
| CGEM | 10%+ Owner | 7,648,268 | $14.54 | $111.21M | -$12.62M | 5 | 2021-09-20 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | 10%+ Owner | 637,490 | $23.01 | $14.67M | -$7.08M | 2 | 2021-06-02 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 95,186 | $18.62 | $1.77M | $904.0K | 1 | 2017-11-06 |
Recent Filings · Page 2 of 2
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-31 | CGEM | Sell (S) | −133,074 | -$3.89M | EDGAR |
| 2021-06-02 | Harpoon Therapeutics, Inc. (HARP) Delisted | Sell (S) | −287,470 | -$5.93M | EDGAR |
| 2021-05-06 | Harpoon Therapeutics, Inc. (HARP) Delisted | Sell (S) | −50,860 | -$1.15M | EDGAR |
| 2021-04-09 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | −288,260 | -$6.50M | EDGAR |
| 2020-07-30 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | +30,311,100 | $30.40M | EDGAR |
| 2017-11-06 | Viracta Therapeutics, Inc. (SNSS) Delisted | Buy (P) | +326,000 | $904.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.